Vaccine against HBV and HPV

Details Vaccine against HBV and HPV Vaccine against HBV and HPV

2008-05-13

2008-05-13

Salimi, Ali R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S227100

Reexamination Certificate

active

10983451

ABSTRACT:
Novel combined vaccine compositions are provided, comprising a hepatitis B viral antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, a herpes simplex viral antigen, a VZV antigen, aToxoplasma gondiiantigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.

REFERENCES:
patent: 5776468 (1998-07-01), Hauser et al.
patent: WO 92/11291 (1992-07-01), None
patent: WO 93/19780 (1993-10-01), None
patent: WO 94/21292 (1994-09-01), None
patent: WO 95/17209 (1995-06-01), None
patent: WO 95/17210 (1995-06-01), None
patent: WO 99/45957 (1999-09-01), None
patent: WO 01/17551 (2001-03-01), None
Michel et al, Virology, 2002, vol. 294, pp. 47-59.
Tindle, et al., “Chimeric Hepatitis B Core Antigen Particles Containing B- and Th-Epitopes of Human Papillomavirus Type 16 E7 Protein Induce Specific Antibody and T-Helper Responses in Immunised Mice”.Virology, 200: 547-557 (1994).

Affiliated with

Also associated with

Rating

Vaccine against HBV and HPV does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccine against HBV and HPV, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine against HBV and HPV will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3928913